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osting by EAbstract Recently, signiﬁcant progress has been made through the application of peroxisome pro-
liferator activated receptor-c (PPAR-c) agonists as anti-inﬂammatory drugs that are efﬁcacious, rel-
atively free of side effects, and can be used effectively for a long time. The present study was
designed to evaluate the dose–response relationship of the anti-inﬂammatory activity of telmisartan
in rat models of chronic inﬂammation. The study protocol includes four stages: First stage: 48 rats
were allocated into eight groups, each containing six rats, for the study of the anti-inﬂammatory
activity of different doses of telmisartan in rat model of formaldehyde-induced chronic inﬂamma-
tion. Second stage: six rats were used to study the anti-inﬂammatory activity of telmisartan (1.5 mg/
kg) in combination with dexamethasone (0.5 mg/kg) in the same model. Third stage: 48 rats were
allocated into eight groups, each containing six rats, for the study of the anti-inﬂammatory activity
of telmisartan in rat model of cotton pellet-induced granuloma. Fourth stage: six rats were used to
study the anti-inﬂammatory activity of telmisartan (1.5 mg/kg) when used as adjuvant with dexa-
methasone (0.5 mg/kg) in the same model. Telmisartan in a dose-dependent pattern (0.1, 0.2. 0.4,
0.6, 1.5, 3 mg/kg) signiﬁcantly suppressed inﬂammation in rat models of formaldehyde-induced901712624.
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30 W.K.G. Al-Hejjaj et al.chronic inﬂammation and cotton pellet-induced granuloma. When combined with dexamethasone,
telmisartan (1.5 mg/kg body weight) signiﬁcantly suppressed inﬂammation in both models, which is
signiﬁcantly higher than all of the effects produced by other approaches of treatment when telmi-
sartan used alone. In conclusion, telmisartan decreased formaldehyde-induced chronic inﬂamma-
tion and cotton-pellet induced granuloma in rats in a dose-dependent pattern. Therefore, it may
be considered as a potential treatment for chronic inﬂammatory conditions in human.
ª 2010 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Angiotensin II, the central product of the renin–angiotensin
system, induces oxidative stress and inﬂammation by activat-
ing the angiotensin II type 1 (AT1) receptor (Welch, 2008).
Telmisartan is a highly selective AT1-receptor antagonist ap-
proved for treatment of hypertension. On the other hand, tel-
misartan acts as a partial agonist on the nuclear peroxisome
proliferator-activated receptor-c (PPAR-c) that has been re-
ported to exert anti-oxidative and anti-inﬂammatory effects
(Benson et al., 2004). Recently, telmisartan has been reported
to have additional peroxisome proliferator-activated receptor-
gamma (PPAR-c) partial agonist activity which regulates met-
abolic and inﬂammatory pathways, and improves left ventric-
ular functions (Benson et al., 2004; Schupp et al., 2004). It has
also been demonstrated to have beneﬁcial effect on post-infarct
ventricular remodeling (Geng et al., 2006). With these dual
actions, telmisartan provides additional beneﬁcial pleiotropic
effects such as anti-inﬂammatory, antioxidative and antiprolif-
erative effects in atherosclerosis and myocardial infarction
(Imayama et al., 2006; Takaya et al., 2006). On the other hand,
telmisartan does not have adverse effects like ﬂuid retention
and edema of clinically used full PPAR-c agonists such as
pioglitazone and rosiglitazone (Goebel et al., 2006). Also, can-
disartan and telmisartan signiﬁcantly attenuated gastric muco-
sal lesions induced by cold-restraint stress and indomethacin in
nondiabetic rats (Pavel et al., 2008; Morsy et al., 2009).
Although telmisartan has the potential to interfere with the
inﬂammatory reaction cascade, the dose–response relationship
in animal models of inﬂammation and comparative study with
other anti-inﬂammatory agents is not clear enough to establish
the required dose for this effect. Therefore, the present study
was designed to investigate the dose–response relationship of
the anti-inﬂammatory activity of telmisartan in animal models
of chronic inﬂammation.2. Experimental
2.1. General
Telmisartan powder (Boehringer Ingelheim, Germany) was
dissolved in distilled water to produce a stock solution of
0.4 mg/ml, from which different doses were prepared accord-
ing to the body weight of the animals. Sprague–Dawley rats
weighing 180–220 g of both sexes were purchased from the
National Centre for Drug Research and Quality Control,
Baghdad. They were kept in the animal house of the Depart-
ment of Pharmacology and Toxicology, College of Pharmacy,
University of Baghdad, at 25 ± 2 C and light:dark cycle of
12:12 h for 1 week before starting experiments. Animals were
provided with standard rodent pellet diet and the food waswithdrawn 12 h before the experiment, though water was
allowed ad libitum. All experiments were performed according
to the guidelines of laboratory animals care and the ethical
guidelines for the investigations on experimental animals. In
the present study, 108 rats were allocated into 18 groups (six
rats each) and the study protocols were divided into four
stages: First stage: 48 rats were used, and allocated into eight
groups for the study of the anti-inﬂammatory activity of
telmisartan in rat model of formaldehyde-induced chronic
inﬂammation. Second stage: six rats were used to study the
anti-inﬂammatory activity of the maximum effective dose of
telmisartan obtained from ﬁrst stage when used in combina-
tion with dexamethasone (0.5 mg/kg) (American reagent,
USA) in rat model of formaldehyde-induced chronic inﬂam-
mation. Third stage: 48 rats allocated into eight groups for
the study of the anti-inﬂammatory activity of telmisartan in
rat model of cotton pellet-induced granuloma. Fourth stage:
six rats were used for the study of the anti-inﬂammatory activ-
ity of the maximum effective dose of telmisartan when used in
combination with dexamethasone (0.5 mg/kg) in rat model of
cotton pellet-induced granuloma.
2.2. Formalin-induced chronic inﬂammation
The anti-inﬂammatory effect of telmisartan in chronic inﬂam-
mation was evaluated by formalin-induced paw edema (Chau,
1989). In this model, chronic inﬂammation was induced by
injecting 0.1 ml of 2% formalin (Al-Jubail, Saudi Arabia) into
the sub-plantar area of the right hind paw of ether anaesthe-
tized rats. All drugs including telmisartan (0.1, 0.2, 0.4, 0.6,
1.5, and 3 mg/kg body weight), dexamethasone 1 mg/kg and
distilled water 2 ml/kg were given 30 min prior to formalin
injection and continued for seven consecutive days. All drugs
and the vehicle were given orally once daily using oral gavage
needle. In this model, the increase in paw edema was measured
by vernier caliper method (Joseph et al., 2005). In vernier cal-
iper method, the paw thickness was measured before and
6 days after induction of inﬂammation by using vernier caliper.
The difference in paw thickness after and before induction of
inﬂammation was calculated and presented as mean increase
in paw thickness (mm). The ability of the anti-inﬂammatory
drug to suppress paw inﬂammation was expressed as a percent-
age of inhibition of paw edema (Duffy et al., 2001).
2.3. Cotton pellet-induced granuloma
The anti-inﬂammatory activity of telmisartan was evaluated
using cotton pellets-induced granuloma according to the meth-
od of Winter and Porter (1957). Cotton pellets weighing
10 ± 1 mg were sterilized in an autoclave for 30 min at
120 C under 15 Ib pressure. Four pellets were implanted sub-
cutaneously (s.c.) into the ventral region, two on either side, in
Table 1 Effects of different doses of telmisartan and its combination with dexamethasone on paw thickness and inhibition of paw
edema (%) in formaldehyde-induced chronic inﬂammation in rats.
Treatment groups Mean paw
thickness (mm)
at zero time
Mean paw
thickness (mm)
after 7 days
Mean increase in
paw thickness (mm)
after 7 days
Inhibition of
paw edema
(%)
Distilled water 3.22 ± 0.07 7.00 ± 0.05* 3.78 ± 0.09a –
Telmisartan 0.1 mg/kg 3.28 ± 0.06 5.86 ± 0.10* 2.58 ± 0.11b 16.28
Telmisartan 0.2 mg/kg 3.14 ± 0.1 5.42 ± 0.02* 2.28 ± 0.10c 22.71
Telmisartan 0.4 mg/kg 3.12 ± 0.04 5.28 ± 0.01* 2.16 ± 0.04c 24.71
Telmisartan 0.6 mg/kg 3.13 ± 0.05 5.17 ± 0.03* 2.04 ± 0.06c 26.14
Telmisartan 1.5 mg/kg 3.15 ± 0.09 4.74 ± 0.05* 1.58 ± 0.10d 32.42
Telmisartan 3 mg/kg 3.20 ± 0.08 4.24 ± 0.04* 1.04 ± 0.09e 39.42
Telmisartan 1.5 mg/kg + 0.5mg/kg
dexamethasone
3.19 ± 0.05 3.80 ± 0.05* 0.61 ± 0.07f 45.71
Dexamethasone 1 mg/kg 3.21 ± 0.06 3.27 ± 0.06 0.05 ± 0.08g 53.42
Data are expressed as mean ± standard error; n= 6 animals in each group; *signiﬁcantly different compared to control (P< 0.05); values with
non-identical superscripts (a, b, c, d, e, f, g) were considered signiﬁcantly different (P< 0.05).
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cle were administered as mentioned before for seven consecu-
tive days before the day of cotton pellet implantation. On
8th day the animals were anaesthetized and the pellets together
with the granuloma tissues were carefully removed and made
free from extraneous tissues. The wet pellets were weighed
for the determination of wet weight, and then dried in an incu-
bator at 60 C for 18 h until a constant weight obtained (all the
exudates dried); after that the dried pellets were weighed again.
The exudate amount (mg) was calculated by subtracting the
constant dry weight of pellet from the immediate wet weight
of pellet. The granulation tissue formation (dry weight of gran-
uloma) was calculated after deducting the weight of cotton pel-
let (10 mg) from the constant dry weight of pellet and taken as
a measure of granuloma tissue formation. The percent inhibi-
tions of exudate and granuloma tissue formation were
determined.Figure 1 Dose–response relationship of the effect of telmisartan
on percent inhibition of paw edema in formaldehyde-induced
chronic inﬂammation in rats.2.4. Statistical analysis
All results were expressed as mean ± SEM. The signiﬁcance of
differences between treated groups was determined using
Student’s t-test and one-way analysis of variance (ANOVA).
P-values < 0.05 were considered signiﬁcant.3. Results
3.1. Anti-inﬂammatory activity in formalin-induced chronic
inﬂammation
In Table 1, all telmisartan doses (0.1, 0.2, 0.4, 0.6, 1.5, and
3 mg/kg body weight) signiﬁcantly reduced the increases in
paw thickness (in a dose-dependent pattern) compared to con-
trols, with maximum effect produced by 1.5 mg/kg (32.2%) and
3.0 mg/kg (39.42%), respectively. Meanwhile, 1 mg/kg dexa-
methasone signiﬁcantly inhibited the increases in paw thickness
compared to controls (53.42%). Telmisartan (1.5 mg/kg body
weight), when administered with dexamethasone (0.5 mg/kg
body weight), resulted in 45.71% decrease in paw edema, which
was signiﬁcantly higher than all of the effects produced by
telmisartan alone. In Fig. 1, the dose–response relationship ofthe anti-inﬂammatory activity of telmisartan was found to be
relatively linear within the dose ranges utilized in this study,
with best linearity between 0.6 and 3 mg/kg.
3.2. Anti-inﬂammatory activity in cotton pellet-induced
granuloma
Table 2 shows that all telmisartan doses signiﬁcantly decreased
the formation of inﬂammatory exudate (in a dose-dependent
pattern) compared to controls, with the maximum effect
produced by 1.5 mg/kg (34.01%) and 3 mg/kg (47.47%).
Meanwhile, 1 mg/kg of dexamethasone signiﬁcantly inhi-
bited exudate formation compared to controls, and the largest
effect was produced by dexamethasone (49.04%). Telmisartan
(1.5 mg/kg body weight) in combination with dexamethasone
(0.5 mg/kg body weight) resulted in (48.30%) decrease in exu-
date formation, which was signiﬁcantly higher than all of the
effects produced by telmisartan alone. In Fig. 2, the dose–
Table 2 Effects of different doses of telmisartan and its combination with dexamethasone on mean weight of exudates and inhibition
of exudates (%) in cotton pellet-induced chronic inﬂammation in rats.
Treatment groups Mean weight of exudates (mg) % inhibition of exudate
Distilled water 108.5 ± 0.84 –
Telmisartan 0.1 mg/kg 100.4 ± 0.31*a 7.47
Telmisartan 0.2 mg/kg 91.0 ± 0.09*b 16.13
Telmisartan 0.4 mg/kg 89.8 ± 0.12*b 17.24
Telmisartan 0.6 mg/kg 74.9 ± 0.20*c 30.97
Telmisartan 1.5 mg/kg 71.6 ± 0.05*d 34.01
Telmisartan 3 mg/kg 57.0 ± 0.26*e 47.47
Telmisartan 1.5 mg/kg +0.5 mg/kg dexamethasone 56.1 ± 0.15*f 48.30
Dexamethasone 1 mg/kg 55.3 ± 0.12*g 49.04
Data are expressed as mean ± standard error; n= 6 animals in each group; *signiﬁcantly different compared to control (P< 0.05); values with
non-identical superscripts (a, b, c, d, e, f, g) were considered signiﬁcantly different (P< 0.05).
Figure 2 Dose–response relationship of the effect of telmisartan
on exudate inhibition (%) in cotton pellet-induced granuloma in
rats.
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terms of attenuation of inﬂammatory exudate formation)
of telmisartan was found to be relatively linear within the dose
ranges utilized in this study. Meanwhile, telmisartan signiﬁ-
cantly decreased the formation of granuloma (in a dose-
dependent pattern) compared to control, with the maximumTable 3 Effects of different doses of telmisartan and its combinat
inhibition of granuloma (%) in formaldehyde-induced chronic inﬂam
Treatment groups Mean d
Distilled water 31.5 ± 0
Telmisartan 0.1 mg/kg 21.8 ± 0
Telmisartan 0.2 mg/kg 19.1 ± 0
Telmisartan 0.4 mg/kg 18.2 ± 0
Telmisartan 0.6 mg/kg 17.1 ± 0
Telmisartan 1.5 mg/kg 14.7 ± 0
Telmisartan 3 mg/kg 13.0 ± 0
Telmisartan 1.5 mg/kg + 0.5 mg/kg dexamethasone 10.00 ±
Dexamethasone 1 mg/kg 9.0 ± 0.
Data are expressed as mean ± standard error; n= 6 animals in each grou
non-identical superscripts (a, b, c, d, e) were considered signiﬁcantly diffeffect produced by the dose 3.0 mg/kg (58.74%). Meanwhile,
1 mg/kg dexamethasone signiﬁcantly inhibited the formation
of granuloma compared to controls; the maximum effect was
produced by dexamethasone (71.43%) (Table 3). Adjunct use
of telmisartan (1.5 mg/kg body weight) with dexamethasone
(0.5 mg/kg body weight) resulted in 68.26% decrease in the
formation of granuloma, which was signiﬁcantly higher than
all of the effects produced by telmisartan alone. In Fig. 3,
the dose–response relationship of the anti-inﬂammatory activ-
ity (in terms of attenuation of granuloma formation) of telmi-
sartan was found to be relatively linear within the dose ranges
utilized in the present study, with best linearity shown between
0.6 and 3 mg/kg.
4. Discussion
In the present study, formaldehyde- and cotton pellet-induced
inﬂammatory reactions similar to that reported during arthri-
tis, and these animal models, are standard for the evaluation of
therapeutic agents with suspected anti-arthritic activity (Okoli
et al., 2008). As telmisartan signiﬁcantly inhibited inﬂamma-
tory reactions in this model of inﬂammation, it can be pro-
posed that this agent may possess anti-proliferative and anti-
arthritic activities. Tissue injury induces a cascade of cellular
reactions in the lesion area, accompanied with the release of
pro-inﬂammatory cytokines, such as TNF-a, IL-1b, IL-6, IL-
8 and other substances, which is then followed by subsequent
inﬂammatory reactions (Hua et al., 1996). Prostaglandins suchion with dexamethasone on mean weight of dry granuloma and
mation in rats.
ry weight of granuloma (mg) Granuloma inhibition (%)
.16 –
.17*a 30.8
.02*b 39.37
.03*b 42.23
.02*c 45.72
.04*d 53.34
.03*d 58.74
0.15*e 68.26
12*e 71.43
p; *signiﬁcantly different compared to control (P< 0.05); values with
erent (P< 0.05).
Figure 3 Dose–response relationship of the effect of telmisartan
on granuloma inhibition (%) in cotton pellet-induced granuloma
in rats.
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inﬂamed tissues like rheumatoid synovium, increase local
blood ﬂow and potentiate the effects of mediators such as bra-
dykinin that induce vasopermeability (Yoshida et al., 2006).
Meanwhile, many studies suggested that activation of PPAR-
c with many classes of ligands (including telmisartan) may de-
crease production of the hypertrophic prostanoids PGE2, with
consequent amelioration or modulation of some component of
inﬂammation (Norihiro et al., 2006). Telmisartan, the selective
AT1 receptor antagonist, was proved effective in reducing the
generation of reactive oxygen species and pro-inﬂammatory
mediators. The antioxidant and anti-inﬂammatory effects of
telmisartan are related to its ability to prevent the activation
of nuclear factor-jB signaling pathway which promotes the
transcription of NADPH oxidase, tumor necrosis factor-a
and inducible nitric oxide synthase genes (Takaya et al.,
2006; Morishima et al., 2009). This is in agreement with the
present results which revealed that telmisartan treatment sig-
niﬁcantly prevented the formation of inﬂammatory edema
due to challenge with formalin, and suppressed both exudate
and granulation tissue formation as a result of subcutaneous
cotton pellet implantation. Other mechanisms independent of
AT1 receptor blockade are responsible for the antioxidant
and anti-inﬂammatory activities of telmisartan. The drug acts
as a partial agonist at the PPar-c (Benson et al., 2004). Activa-
tion of this receptor induces catalase gene expression and
inhibits nuclear factor-jB, thus combating oxidative stress
and down regulating most of the pro-inﬂammatory responses
(Blessing et al., 2008). In addition, the anti-inﬂammatory effect
of telmisartan observed in the present study can be attributed
to its PPAR-c agonist activity. The fact that expression of
PPAR-c was modulated during the course of many inﬂamma-
tory disorders represents the solid base for the use of highly
effective PPAR-c ligands for the aim of attenuation and/or
modulation of the course of inﬂammation. Altered expression
of PPAR-c was observed in several other inﬂammatory disor-
ders. For instance, PPAR-c expression was shown to be re-
duced in many pathological conditions of inﬂammatorybases including atherosclerotic tissues (Klotz et al., 2005), in
peripheral blood mononuclear cells from patients with multi-
ple sclerosis (Kitamura et al., 1999) and in alveolar macro-
phages from patients with allergic asthma (Benayoun et al.,
2001). Meanwhile, ligand activation of PPAR-c down regu-
lates the transcription of genes encoding inﬂammatory mole-
cules, inﬂammatory cytokines, growth factors, proteolytic
enzymes, adhesion molecules, and chemotactic factors (Koji
et al., 2007; Qingping et al., 2009). Such ﬁnding gives a hope
for conducting trials to evaluate the anti-inﬂammatory activity
of potent PPAR-c activators, including telmisartan and other
ARBs, when the safety concern of these agents was completely
resolved. Therefore, a possible involvement of PPAR-c in the
attenuation of inﬂammatory response afforded by telmisartan
in animal models of chronic inﬂammation utilized in the pres-
ent study cannot be excluded. However, this needs to be con-
ﬁrmed by further investigations.
5. Conclusion
In conclusion, telmisartan, in a dose-dependent pattern, was
effective in attenuating formaldehyde-induced paw edema
and cotton-pellet-induced granuloma in rat models of chronic
inﬂammation, and therefore it could be investigated as a
potential treatment for chronic inﬂammatory conditions in
humans.
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